Recent data shows positive attitudes for decentralized trials in rare disease patients

Jeremy Edwards, our CEO, discusses the findings from our clinical trial opinions survey and what they mean for pharma in the Applied Clinical Trials publication

Decentralized clinical trials are already a hot area of interest for CROs and sponsors, but how do patients feel about them, particularly those living with rare diseases? That’s what we aimed to find out with our recent survey. We surveyed people around the world living with the following conditions: hemophilia, idiopathic pulmonary fibrosis (IPF), myasthenia gravis (MG), and sickle cell disease. Participants were asked about their attitudes and opinions around clinical trials and whether topical factors like COVID-19 had an impact.

Get in touch

Interested in hearing more? Feel free to reach out to us, and we’ll make sure to get back to you as soon as possible.